What is the LINKER-MM3 clinical research study?

If you live with relapsed or refractory multiple myeloma (MM), please know that you are not alone in your medical journey. Multiple myeloma is a cancer of the plasma cells and accounts for approximately 13% of all cancers of the blood.
Currently, we are developing potential treatments for MM. LINKER-MM3 is a clinical research study that aims to test the safety, tolerability (how your body reacts) and efficacy (reduction in the number of cancer cells in your blood) of a potential MM treatment compared to standard treatments. This treatment is called "investigational" as it has not been approved for use outside this study.

Eligibility >>

Questionnaire

What are the study drugs?

Investigational study drug: This treatment is given by intravenous (IV) infusion (a needle in your arm). The investigational treatment is a bispecific antibody. Antibodies are proteins produced by your immune system to fight infections. The study drug antibody attaches to proteins on 2 different cell types: BCMA on plasma cells and CD3 on a type of immune cell called T-cells. When T-cells are linked to myeloma cells (cancerous plasma cells) by the study drug, it triggers your body’s immune system to attack the myeloma cells and remove them in the same way as if they were fighting an infection.

Comparator treatment: This treatment has already been approved to treat MM. It is a combination of three medications, one of which will be administered by IV infusion. The other two can be taken in pill form. The comparator treatment activates your immune system’s natural killer cells to attack and kill cancerous myeloma cells.

Once the study doctor confirms that you qualify, you will be randomly assigned to 1 of 2 treatment groups. You will have an equal chance of receiving either one of these treatments, similar to flipping a coin. No matter which treatment group you participate in, you will receive treatment for your MM.

What can I expect if I participate?

Study participation is 100% voluntary (your choice). You will receive information on what to expect, as well as your roles and responsibilities if you join the LINKER-MM3 study. You may leave the study at any time without it affecting your regular healthcare.

If you join the study, there are certain things you will be expected to do. This includes attending study visits and undergoing certain assessments and procedures, including bone marrow aspirates and imaging scans. The length of your participation will depend on your response to the study drugs, and you will be asked to complete study treatment visits from once a week to once a month.

You will be reimbursed for travel to and from study visits, and medical care related to your participation, including the study treatment, will be provided at no cost. However, you or your health insurance will be responsible for treatments and procedures that are part of your standard MM care. The study team is available to discuss all of this with you.

How can I take part?

If you wish to take part in LINKER-MM3, you will need to fill in a short pre-screener questionnaire to see if you may be eligible.

Eligibility >>

Questionnaire

What else should I know?

As with all treatments, there are possible risks when taking the investigational treatment. If you qualify and choose to participate, you will be provided with an Informed Consent Form that explains any possible risks and side effects. It is also possible that the study drugs may affect you in unknown ways. Your health and safety are our top priorities and will be closely monitored throughout your participation.
There is no guarantee that you will receive a medical benefit from participating in this study. Your condition may get better, stay the same or may even get worse. You are free to withdraw from the study for any reason and at any time.

Find a study site near you

To find out more about LINKER-MM3 and whether it may be right for you, please contact your closest study site – they will be more than happy to help.

Find your nearest study site >>

Site Finder

Am I Eligible?

If you wish to take part in the LINKER-MM3 clinical research study, fill in the pre-screener questionnaire below to see if you may be eligible.
You may be eligible if you:
• Are ≥ 18 years old
• Were diagnosed with relapsed or refractory MM
• Have had between 1-4 treatments for MM including lenalidomide
• Are not pregnant, breastfeeding or planning to become or get your partner pregnant
There are other requirements for participation. A full medical check-up will be done to see if you can join this study. If you have other questions, share this website with your doctor to discuss this study.

Pre-screening questionnaire

You can see if you meet some of the requirements by completing the pre-screening questionnaire below. Just answer either “yes” or “no” to each question, then click the “submit” button. This questionnaire is completely anonymous – none of your personal data are saved.

This questionnaire does not contain all of the requirements you need to meet to participate. If you are eligible for this study, you will also receive a copy of the Informed Consent Form when you first visit the study site, which will include additional information.
  • Please click on the answer that best applies to you.

Find a study site near you

To find your nearest study site, please enter your postcode.